Custom Antibody Market 2024 – Market Size & Segments Analysis, Industry Trends, Manufacturers Analysis, Opportunities and Forecast 2034

The custom antibody is referred to the protein that are produced in order to attack the foreign substances that enters the body, causing variety complications to the body that includes digestive issues, cardiovascular problems and allergic infections.   

MARKET OVERVIEW 

The market valuation of the custom antibody market was valued at approximately USD xx billion in 2023 and is projected to reach USD xx billion in 2034 exhibiting a CAGR of xx.x% during the forecast period of 2024-2034. The market is aligned with healthcare sector, which makes it a sustainable and growing market.  

GROWTH DRIVERS 

The rise in the incidence of infectious and chronic disease drives the demand of the market for custom antibodies in therapeutics as well as in research. As per CDC (Centers for Disease Control and Prevention), the number of outbreaks is increasing for diseases such as cholera and viral hemorrhagic fevers coupled with the spread of diseases is accelerating due to vector range expansion for diseases such as dengue and yellow fever; and the morbidity and mortality from antimicrobial-resistant pathogens is increasing dramatically.

Moreover, the growth in cancer immunotherapy and biomarker discovery is another significant driver of the market where cancer plays a crucial role in cancer diagnostics. According to Union for International Cancer Control, the cancer cases are projected to increase to 35 million by 2050, highlighting the need for improved healthcare infrastructure and access to cost-effective cancer services.  

MARKET SEGMENTATION: 

·         By Service- Antibody development, antibody production and purification, antibody fragmentation and labeling 

·         By Type – polyclonal antibodies, monoclonal hybridoma, recombinant proteins and others 

·         By Source – rabbits, chickens, goats, guinea pigs, mice and others  

·         By Application- research and therapeutics 

·         By Indication- oncology, infectious diseases, neurology, stem cells, immunology, cardiovascular diseases  

·         By End Users- pharmaceutical and biotechnology companies, academic and research institutes, CROs and CDMOs 

·         By Regions- North America, Europe, Asia Pacific, South America, Middle East and Africa

Custom Antibody Market Segment by Service Review: 

The custom antibody production service includes the solutions from antigen design to purification and screening to labeling. The service also includes distinguishing among even highly related proteins within complex mixtures to characterize protein expression patterns using IHC, ICC, IF, FACS, ELISA, western blotting, or immunoprecipitation (IP, Co-IP, ChIP).  

Custom Antibody Market Segment by Source Review: 

There are different types of sources such as rabbits, chickens, goats, etc., for the development of custom antibody each favored due to their uniqueness, like rabbits are increasingly used fir the robust immune response, allowing the development of high affinity antibodies. Whereas, antibodies derived from goat are high quality secondary antibodies and are capable to generating high volume of serum.     

Regional Analysis: 

North America is a significant market driven by the presence of key global players coupled with the regional technological advancements as the region is known for innovation. Europe is another significant market driven by the strong presence of government initiatives and strong research capabilities. APAC is significantly growing market driven by rise in research and development spending coupled with rise in prevalence of chronic diseases. MEA region is a promising market driven by the investments in healthcare infrastructure. South America market is projected to grow driven by rising incidence of chronic diseases like cancer coupled with increased focus on healthcare.  

Key Challenges: 

The key challenges faced by the market is that the custom antibody including substantial investment for the development and production coupled with regulatory hurdles. The navigation through diverse landscape may lead to time consuming process, delaying the process and moreover, adding extra cost.

Competitive Landscape: 

In the highly competitive custom antibody market, companies are investing heavily in research and development to innovate and improve their products and services. They are also collaborating, forming strategic partnerships, or acquiring other companies to gain access to new market segments, enhance distribution networks, and increase market share. The key news and development includes- In May 2021, a UK-based startup in biotech, Antiverse, announced to raise a USD 1.72 million (GBP 1.4 million) fund through venture capitalists.

The fund is expected to be used in developing an AI-based antibody discovery technology to enhance antibody-based drug development by accurately projecting antigen-antibody binding. The development of supplement technologies and increased funding is expected to boost the overall market. The Native Antigen Company is a developer and manufacturer of antibodies and antigens along with a service provider to the biopharma and diagnostic sectors.

In December 2022, the company announced to expand its antibodies and antigen portfolio in the infectious diseases segment and design the product to support vaccines and immunoassay development.

In October 2022, Taconic Biosciences announced the launch of an immunodeficient mouse model, the FcResolv NOG portfolio, which lacks murine Fc gamma receptors. According to the company, this model is expected to support antibody-based therapies during the preclinical stage, since the product allows researchers to assess candidates without the interference of residual murine Fc gamma receptor activity.

In October 2022, Kemp Proteins announced receiving a contract from the U.S. FDA to develop monoclonal antibodies to influenza and COVID-19 molecules. The U.S. FDA lab is expected to use antibodies in the development of in-vitro assays for the potency release of influenza and COVID-19 vaccines. 

Global Key Players:  

·         Thermo Fisher

·         GenScript

·         Bio-Rad laboratories

·         Merck

·         Agilent

·         Danaher Corporation

·         Revvity

·         Eurogentec

·         Abmart

·         RayBiotech

·         Other Players